LNCaP androgen-independent cell line
Invented at Northern Institute For Cancer Research, Newcastle University
- Datasheet
- References (0)
- Inventor Info
Info
| Catalogue Number | 154164 |
| Parental Line | LNCaP |
| Host | Human |
| Disease Keywords | Human prostate adenocarcinoma |
| Model | Tumour line |
| Relevance |
LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist. This cell line is the most commonly used for prostate cancer research. The cell line is a clonal population of LNCaP cells grown in steroid-depleted conditions for ~4 months. Cells adapted to growth conditions and are now routinely grown in media lacking testosterone |
| Production Details | LNCaP cells grown in steroid-depleted conditions for ~4 months |
| Conditional | No |
| Research Area | Cancer |
| Recommended Growing Conditions | RPMI-1640 + 10% FBS |
References
There are 0 reference entries for this reagent.
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
References: 0 entry
There is no reference for this reagent yet, feel free to use the button below to suggest one.
Add a reference
